JP2021519285A - ダブラフェニブ、トラメチニブ及びｅｒｋ阻害剤を含む医薬品の三重の組合せ - Google Patents

ダブラフェニブ、トラメチニブ及びｅｒｋ阻害剤を含む医薬品の三重の組合せ Download PDF

Info

Publication number
JP2021519285A
JP2021519285A JP2020551481A JP2020551481A JP2021519285A JP 2021519285 A JP2021519285 A JP 2021519285A JP 2020551481 A JP2020551481 A JP 2020551481A JP 2020551481 A JP2020551481 A JP 2020551481A JP 2021519285 A JP2021519285 A JP 2021519285A
Authority
JP
Japan
Prior art keywords
cancer
combination
trametinib
dabrafenib
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519285A5 (enExample
Inventor
ジョン メイヤー，マシュー
ジョン メイヤー，マシュー
ワン，ヨウツェン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021519285A publication Critical patent/JP2021519285A/ja
Publication of JP2021519285A5 publication Critical patent/JP2021519285A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020551481A 2018-03-30 2019-03-29 ダブラフェニブ、トラメチニブ及びｅｒｋ阻害剤を含む医薬品の三重の組合せ Pending JP2021519285A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650744P 2018-03-30 2018-03-30
US62/650,744 2018-03-30
PCT/IB2019/052601 WO2019186488A1 (en) 2018-03-30 2019-03-29 A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor

Publications (2)

Publication Number Publication Date
JP2021519285A true JP2021519285A (ja) 2021-08-10
JP2021519285A5 JP2021519285A5 (enExample) 2022-04-06

Family

ID=66397350

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551481A Pending JP2021519285A (ja) 2018-03-30 2019-03-29 ダブラフェニブ、トラメチニブ及びｅｒｋ阻害剤を含む医薬品の三重の組合せ

Country Status (13)

Country Link
US (1) US20210121460A1 (enExample)
EP (1) EP3773586A1 (enExample)
JP (1) JP2021519285A (enExample)
KR (1) KR20200138303A (enExample)
CN (1) CN111936141A (enExample)
AU (1) AU2019246719B2 (enExample)
BR (1) BR112020019577A2 (enExample)
CA (1) CA3094780A1 (enExample)
CL (1) CL2020002505A1 (enExample)
IL (1) IL277380A (enExample)
MX (1) MX2020010231A (enExample)
RU (1) RU2020135055A (enExample)
WO (1) WO2019186488A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230090389A1 (en) * 2020-02-28 2023-03-23 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
IL295626A (en) * 2020-02-28 2022-10-01 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
KR20240055721A (ko) * 2021-06-24 2024-04-29 아사나 바이오사이언시스 엘엘씨 Erk1/2 억제제 조합 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540728A (ja) * 2013-11-01 2016-12-28 ノバルティス アーゲー キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540728A (ja) * 2013-11-01 2016-12-28 ノバルティス アーゲー キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANCER DISCOVERY, vol. 5, no. 4, JPN6023002809, 2015, pages 348 - 350, ISSN: 0004977696 *
CANCER RESEARCH, vol. Vol.76, No.14 Spplement, JPN6023002806, 2016, pages 2150, ISSN: 0004977697 *
MOLECULAR ONCOLOGY, vol. 8, JPN6023002808, 2014, pages 544 - 554, ISSN: 0004977695 *
NATURE MEDICINE, vol. 23, no. 8, JPN6023002807, 2017, pages 929 - 937, ISSN: 0005138717 *

Also Published As

Publication number Publication date
CA3094780A1 (en) 2019-10-03
CN111936141A (zh) 2020-11-13
BR112020019577A2 (pt) 2021-01-05
IL277380A (en) 2020-11-30
KR20200138303A (ko) 2020-12-09
CL2020002505A1 (es) 2021-03-05
EP3773586A1 (en) 2021-02-17
AU2019246719A1 (en) 2020-10-01
US20210121460A1 (en) 2021-04-29
AU2019246719B2 (en) 2022-06-16
MX2020010231A (es) 2020-10-28
WO2019186488A1 (en) 2019-10-03
RU2020135055A (ru) 2022-05-05

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
JP2022520079A (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
TW202313041A (zh) 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
US9486445B2 (en) Combination therapy for proliferative disorders
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
CA3223602A1 (en) Erk1/2 and kras g12c inhibitors combination therapy
TW202416986A (zh) 使用ｕｌｋ抑制劑治療病症之方法
TW202207942A (zh) 包含ｃｒａｆ抑制劑的治療組合
CN118201616A (zh) 用于癌症的wee1抑制剂
US20250223348A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
AU2019246719B2 (en) A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor
JP2023534991A (ja) 変異型ｉｄｈ１阻害剤、デオキシアデノシン類似体、及び白金剤を用いた併用療法
US20140303146A1 (en) Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
US20230097085A1 (en) [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
JP2021503448A (ja) Ｌｓｚ１０２及びリボシクリブを含む医薬組合せ
EP2162129B1 (en) Use of hdac inhibitors for the treatment of bone destruction
US20230129787A1 (en) Methods for treating ovarian cancer
US20250275978A1 (en) Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
JP2023516155A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ
EP4719405A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
CN120417928A (zh) 联合治疗肿瘤的药物
CA3223692A1 (en) Erk1/2 inhibitor combination therapy
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
US20240165120A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
HK1141247B (en) Use of hdac inhibitors for the treatment of bone destruction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230829